TY  - JOUR
T1  - CEtp inhibition shows promise as way to reduce cardiovascular disease risk
AU  - Mitka M
Y1  - 2011/01/12
N1  - 10.1001/jama.2010.1908
JO  - JAMA
SP  - 136
EP  - 137
VL  - 305
IS  - 2
N2  - 
Chicago—A major international trial will investigate whether a cholesteryl ester transfer protein (CETP) inhibitor can reduce cardiovascular risk, researchers announced during the Scientific Sessions of the American Heart Association (AHA) held here in November. The study seeks to determine whether lipid modification with anacetrapib reduces the risk of coronary death, myocardial infarction, or coronary revascularization in patients with established vascular disease who are taking a statin to treat elevated low-density lipoprotein cholesterol (LDL-C).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.1908
UR  - http://dx.doi.org/10.1001/jama.2010.1908
ER  -